18 results about "Sequence motif" patented technology

The present invention is in the field of genetic editing tools and methods of genetic endineering. It relates to the engineering of rare-cutting endonucleases designed to contract highly repetitive motives in chromosomes, which are at the origin of certain genetic diseases, in particular the so-called "triplet repeat diseases", such as the Huntington disease. The invention encompasses the method for contracting the repetitive motives, the rare-cutting endonucleases for use to contract repetitive motives in a gene subjected to repeat disorder, the polynucleotides and vectors encoding thereof as well as the resulting pharmaceutical compositions.

The present invention relates to methods for engineering the variable region of antibodies or antigen binding fragments thereof, in particular to reduce the effect of anti-drug antibodies. In one aspect, there is provided a monoclonal antibody or antigen-binding fragment thereof, wherein an amino acid sequence of the antibody or fragment thereof is engineered to reduce immunogenicity of the antibody or fragment thereof when the antibody or fragment thereof is administered to a subject, wherein the amino acid sequence is engineered to comprise one or more N-X-S and / or N-X-T sequence motifs in a variable region of the monoclonal antibody or fragment thereof, and wherein X is any amino acid other than proline.

The present invention relates to a nutritionally optimized synthetic or recombinant collagen peptide comprising at least one amino acid sequence motif (glycine-X-Y)n, and the collagen peptide according to the invention for use in a method for therapeutic treatment of the human or animal body and products containing the collagen peptide according to the invention.

Described herein are olfactory receptor proteins having a modified C-terminal domain comprising a specific amino acid sequence motif, as well as related nucleic acid molecules, expression vectors, recombinant host cells, libraries, and methods and uses.

The present invention relates to a synthetic DNA construct comprising (A) a nucleic acid encoding transfer RNA and (B) a 5' leader sequence, wherein the 5' leader sequence contains a sequence motif for controlling the expression level of the transfer RNA.

The present invention relates to methods for engineering the variable region of antibodies or antigen binding fragments thereof that bind TNF alpha to reduce the effect of anti-drug antibodies. In one aspect, there is provided a monoclonal antibody or antigen-binding fragment thereof, wherein an amino acid sequence of the antibody or fragment thereof is engineered to reduce immunogenicity of the antibody or fragment thereof when the antibody or fragment thereof is administered to a subject, wherein the amino acid sequence is engineered to comprise one or more N-X-S and / or N-X-T sequence motifs in a variable region of the monoclonal antibody or fragment thereof, and wherein X is any amino acid other than proline.

Disclosed herein are polypeptides comprising an extended recombinant polypeptide (XTEN) comprised of a plurality of overlapping sequence motifs and one or more barcode fragments releasable upon protease digestion and detectable from ail other proteolytic-ally releasable fragments. Certain embodiments of these polypeptides further comprise a biologically active polypeptide, wherein advantageous embodiments thereof comprise a releasable segment capable of proteolytic cleavage that cleaves the linkage between the XTEN polypeptide and the biologically active polypeptide. Methods of making and methods of using said polypeptides are also disclosed.

A grade of a specific microbial disease in a biological sample of a subject is determined. In one example, masked microbial reference genomes are used to determine the amount of free DNA molecules corresponding to a particular microbial species associated with a particular microbial disease. The masking may remove an area shared with another. In another example technique, end motifs are used for free DNA fragments from a subject and from a particular microbial species. A correlation between a subject and an amount of a set of terminal sequence motifs of a particular microbial species may be determined. The two groups of quantities of positive subjects are substantially more correlated than negative subjects.

A method of analyzing a cfDNA from a biological sample to determine a level of a pathology in the biological sample of a subject comprises (i) determining an end sequence motif of at least one end of

A method for identifying adjacent sequence motifs, potency and specificity of nuclease is disclosed.

The present invention relates to barcoded XTEN polypeptides and compositions thereof and methods of making and using the same, specifically disclosing polypeptides comprising an extended recombinant polypeptide (XTEN) comprising a plurality of overlapping sequence motifs and one or more barcode fragments that are releasable upon protease digestion and detectable from all other proteolytically releasable fragments. Certain embodiments of these polypeptides further comprise a biologically active polypeptide, with advantageous embodiments thereof comprising a proteolytic cleavage releasable segment capable of cleaving the linkage between the XTEN polypeptide and the biologically active polypeptide. Methods of making the polypeptides and methods of using the polypeptides are also disclosed.

Disclosed is a method for diagnosing cancer and predicting a cancer type using fragment end motif frequencies and sizes of cell-free nucleic acid, and more preferably, to a method for diagnosing cancer and predicting a cancer type by extracting nucleic acids from a biological sample to obtain sequence information, acquiring fragment end motif frequencies and sizes of nucleic acids based on the aligned reads, converting the fragment end motif frequencies and sizes of nucleic acids into vectorized data, inputting the vectorized data to a trained artificial intelligence model and analyzing a resulting calculated value. The method includes generating vectorized data and analyzing the same using an AI algorithm and thus is useful due to high sensitivity and accuracy thereof even in the case of low read coverage.

A method for measuring a fractional concentration of DNA from a first tissue type in a biological sample of a subject, the biological sample comprising cell-free DNA, the method comprises analysing a plurality of cell-free DNA molecules from the biological sample of the subject by (a) determining a genomic position in a reference genome corresponding to at least one end of the cell-free DNA molecule, (b) identifying a first set of CpG sites that all have a first differential methylation for the first tissue type in the reference genome, wherein the first set of CpG sites includes one or more CpG sites, (c) determining a first amount of cell-free DNA molecules ending at one of 0 or -1 position of any one of the first set of CpG sites or alternatively, (c) determining an end sequence motif of at least one end of the cell-free DNA molecule, wherein an end of the cell-free DNA molecule has a first position at an outermost position, a second position that is next to the first position, and a third position that is next to the second position; and (d) determining the fractional concentration of DNA from the first tissue type in the biological sample by comparing the first amount to a calibration value, wherein the calibration value is determined from one or more calibration samples having known fractional concentrations of DNA from the first tissue type.

The invention belongs to the technical field of deep learning, and particularly relates to an interpretable DNA sequence motif extraction and visualization method based on deep learning, and a motif extraction method based on combination of baseline input constructed based on a data set AGCT background and DeepLIFT attribution. A target motif length is parameterized into a normalized cut-off frequency, and a length controllable positioning frequency domain noise suppression scheme is realized through adjustable low-pass filtering; a screened motif set is obtained according to a dual screening standard formed by Fisher single-side inspection, BH-FDR correction and an effect quantity threshold value in a combined mode; an integrated link from site-by-site attribution to frequency domain noise suppression and length adjustability to statistics double-threshold robust screening to database comparison verification is established while the capability of capturing long-short motifs with different scales is ensured; the motif extraction not only can reflect the internal discrimination basis of the model, but also can maintain repeatable, comparable and traceable biological reliability in different data fields and application scenes.

Provided are some techniques that can use size and / or end motifs of cell-free DNA fragments to determine a concentration of cell-free DNA (all or clinically- relevant) in a biological sample of a subject, e.g., as a mass per volume. For example, a measured amount of cell-free DNA fragments at a particular size can be used with one or more calibration amounts determined from one or more calibration samples to determine a concentration of cell-free DNA. As another example, the measured amount can be of cell-free DNA fragments having a set of one or more sequence motifs corresponding to ending sequences of the plurality of cell-free DNA fragments. Certain sequence motif (s) can be selected.

The present invention relates to a Spinacia oleracea plant comprising a nucleic acid molecule which when homozygously present provides at least intermediate resistance to Peronospora effusa races Pe: 1, Pe: 2, Pe: 3, Pe: 4, Pe: 5, Pe: 6, Pe: 7, Pe: 8, Pe: 9, Pe: 10, Pe: 11, Pe: 12, Pe: 13, Pe: 14, Pe: 15, Pe: 16, Pe: 17, Pe: 18, Pe: 19 and Pe: 20, wherein said nucleic acid molecule comprises a gene which comprises a coding sequence according to SEQ ID NO: 1 and a gene which comprises a coding sequence according to SEQ ID NO: 2, or a gene which comprises a coding sequence having at least 95.0% sequence identity to SEQ ID NO: 7 and comprises an insertion of sequence motif GAAATA between nucleotides 1235 and 1236 of SEQ ID NO: 7 and a gene which comprises a coding sequence having at least 95.0% sequence identity to SEQ ID NO: 8 and lacks a sequence according to SEQ ID NO: 14, wherein the 95.0% sequence identity is over the part of SEQ ID NO: 8 without the lacking sequence, or genes comprising the corresponding genomic sequences or genes encoding a protein having an amino acid sequence according to SEQ ID NO: 3, and a gene encoding a protein having an amino acid sequence according to SEQ ID NO: 4, or genes encoding proteins showing 95% sequence identity thereto. The invention further relates to a plant carrying the nucleic acid molecule and to methods of selecting, producing and growing such plants.

The present disclosure is based on the identification of a novel sequence motif present in halogenase type enzymes. From this, the disclosure provides methods for identifying and or detecting halogenases (halogenating enzymes) and novel halogenases identifiable using such methods. The disclosure also provides a novel cohort of enzymes and novel methods for achieving substrate halogenation.

Some techniques of the present disclosure can use size and / or end motifs of cell-free DNA fragments to determine a concentration of cell-free DNA (all or clinically-relevant) in a biological sample of a subject, e.g., as a mass per volume. For example, a measured amount of cell-free DNA fragments at a particular size can be used with one or more calibration amounts determined from one or more calibration samples to determine a concentration of cell-free DNA. As another example, the measured amount can be of cell-free DNA fragments having a set of one or more sequence motifs corresponding to ending sequences of the plurality of cell-free DNA fragments. Certain sequence motif(s) can be selected.